Health Robotics and Grifols Expand Marketing Cooperation Into the United States of America, Replacing McKesson

"After visiting Health Robotics' Robot factory and participating in its technical training this month, I'm very excited to represent Health Robotics' unique IV Automation solutions in the USA, in conjunction with Grifols USA's Hospital Division portfolio of products. Bringing Grifols' collective experience from our Health Robotics' European IV Robot installations to the United States, I look forward to develop unique value propositions for our American customers, reflecting the exclusive patient safety and financial benefits of i.v.STATION, i.v.SOFT, and i.v.STATION ONCO"stated Juan Miguel Cana, Grifols USA Hospital Division's General Manager.
Italy, (informazione.it - comunicati stampa - scienza e tecnologia)

"After visiting Health Robotics' Robot factory and participating in its technical training this month, I'm very excited to represent Health Robotics' unique IV Automation solutions in the USA, in conjunction with Grifols USA's Hospital Division portfolio of products. Bringing Grifols' collective experience from our Health Robotics' European IV Robot installations to the United States, I look forward to develop unique value propositions for our American customers, reflecting the exclusive patient safety and financial benefits of i.v.STATION, i.v.SOFT, and i.v.STATION ONCO"stated Juan Miguel Cana, Grifols USA Hospital Division's General Manager.

"Grifols' cooperation in the USA represents a very positive step in the post-McKesson era for Health Robotics' products in America, giving our company access to an experienced, sizeable, and dedicated Sterile Compounding team. Furthermore, with the release of 1H2011 results next week, 2 additional key partnerships between Health Robotics with American companies will be announced, persisting on the McKesson-replacement strategy path" stated Gaspar DeViedma, Health Robotics' Executive Vice President.

About Grifols:

Grifols is a Spanish holding company, specializing in the hospital-pharmaceutical sector, and with a presence in over 90 countries. Since May 2006 it has been listed on the Spanish Continuous Market, and since 2008 it has been included in the Ibex-35. Grifols is the leading European plasma products company, and the fourth-largest producer in the world. The company plans to strengthen its position within the industry as a vertically integrated company, on the basis of its completed investments and its ongoing program for the period 2008-2012. In terms of raw material, Grifols has secure plasma supplies from its network of 80 plasmapheresis centers in the United States, while its production plants in Barcelona (Spain) and Los Angeles (United States) ensure that it has the fractionation capacity to satisfy rising demand. In addition, the company has implemented an ambitious investment plan to enable it to deliver sustained growth over the next 8 to 10 years. Grifols' Hospital Division focuses on research, development, manufacturing and marketing non-biological products used in hospitals, clinics and infusion centers.  Grifols' Hospital Division products are designed to increase safety and efficiency in the hospital pharmacy. For more information, please visit https://www.grifols.com

About Health Robotics:

Founded in 2006, Health Robotics is the undisputed global leading supplier of life-critical intravenous medication robots, winning 100% of all worldwide IV Robot's publicly announced purchases over the past 18 months, and providing more than 200 hospital installations in 6 continents with robotics-based technology and software automation solutions. Health Robotics' world-leading solutions CytoCare® and i.v.STATION® ONCO [hazardous IVs], i.v.STATION® [non-hazardous IVs], i.v.SOFT® [workflow engine for manual compounding], MEDarchiver® [life-critical clinical information system], and TPNstation™ [totally-automated parenteral nutrition] have and will greatly contribute to ease hospitals' growing pressures to improve patient safety, increase throughput and contain costs. Through the effective and efficient production of sterile, accurate, tamper-evident and ready-to-administer IVs, Health Robotics' products help hospitals eliminate life-threatening drug and diluent exchange errors, decrease other medical mistakes and sterility risks, work more efficiently, reduce waste and controlled substances' diversion, and diminish the gap between rising patient volume/acuity and scarce medical, nursing, and pharmacy staff. For more information, please visit: https://www.health.robotics.com

For specific requests, please contact:

Health Robotics and Grifols Expand Marketing Cooperation Into the United States of America, Replacing McKesson

Juan Miguel Cana, General Manager
juanmiguel.cana@grifols.com
Phone: +1-323-229-0707

Claudia Flaim, Marketing Coordinator
flaim@health-robotics.com

Facebook Twitter GooglePlus Pinterest Linkedin Tumblr
Ufficio Stampa
 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
Allegati
Non disponibili
Health Robotics Announces Record-Breaking 2Q 2011 Results  -  " On the heels of Health Robotics' termination of McKesson's distribution and services contract for cause http://www.health-robotics.com/smartedit/downloads/en/mck.pdf , the company recorded its best-ever American trimester from a customer perspective during its 5 th…
Health Robotics Wins Quick Dismissal of McKesson Corporation's Lawsuit in United States Federal Court  -  " This McKesson dismissal resolves all pending and past litigation against Health Robotics in the United States of America with a 100% winning record in our favor . As a small European company, we are indeed very pleased to see our…
CAMEROBOT Sets New Standards in Broadcasting Automation  -  Bavaria-based Camerobot Systems GmbH has introduced a radical new approach to broadcasting - by bringing state-of-the-art robotics into the studio. Camerobot, a robotic system for automating cameras, features a variety of new technological solutions for longstanding challenges on live and…
BD Diagnostics and Biodiversity Collaborate to Develop Portfolio of Assays on the BD MAX™ System  -  BD Diagnostics, a segment of global medical technology company BD (Becton, Dickinson and Company), and Biodiversity SpA, a private biotechnology company focusing on molecular diagnostics, announced today a regional collaboration to develop and…
AEGON Announces Q2 2011 net Income of EUR 404 Million  -  "During the second quarter, we made solid progress in delivering on AEGON's key strategic priorities, not least of which was the completion of repayment to the Dutch State. The particularly strong sales of variable annuities and pension and retirement products in the United States are a…
Loading....